Paper · 10716624

Fibroblast growth factor-2.

Okada-Ban M and 2 others. Int J Biochem Cell Biol, 2000. Cited by 178 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Cite this record

ConductScience Library. Fibroblast growth factor-2. Papers, record 10716624. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/10716624

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title: Fibroblast growth factor-2.; PubMed
Journal: Int J Biochem Cell Biol; PubMed
Year: 2000; PubMed
Publication types: Journal Article, Research Support, Non-U.S. Gov't, Review; PubMed
PubMed: https://pubmed.ncbi.nlm.nih.gov/10716624/; PubMed
DOI: https://doi.org/10.1016/s1357-2725(99)00133-8; PubMed
The journal: https://conductscience.org/library/journal-index/9508482; PubMed
Citations, by iCite: 178; iCite
Relative citation ratio, by iCite: 3.79; iCite
Revised in PubMed: 2022-03-21; PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Order	Author	Forename
1	Okada-Ban M	M
2	Thiery JP	J P
3	Jouanneau J	J

Source PubMed

Topics10

NLM's MeSH indexing of the paper, its major topics first.

MeSH term	Major
Fibroblast Growth Factor 2	Major topic
Alternative Splicing
Animals
Cell Division
Humans
Mice
Mice, Knockout
Neovascularization, Physiologic
Protein Isoforms
RNA, Messenger

Source PubMed

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References0

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

None in this release.

Cited by68

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 178 citations.

PMID	Title	Journal	Year	In Papers	Source
42,008,023	Identification and Experimental Validation of Biomarkers Associated with PI3K/AKT Signaling Pathway in Spinal Cord Injury.	Mol Neurobiol	2026	https://conductscience.org/library/papers/42008023	PubMed
41,644,787	An integrative genomic analysis of angiogenesis in hepatocellular carcinoma: from canonical drivers to emerging biomarkers.	Naunyn Schmiedebergs Arch Pharmacol	2026	https://conductscience.org/library/papers/41644787	PubMed
41,630,008	Apoptotic vesicles from endothelial cells promote endothelial progenitor cell differentiation and angiogenesis via miR-30a-5p mediated activation of the EGFR/PI3K/AKT/VEGF pathway.	Stem Cell Res Ther	2026	https://conductscience.org/library/papers/41630008	PubMed
41,595,625	Nonthermal Atmospheric Plasma Modulates Palatal Wound Healing in Rats: A Morphometric, Histopathologic and Immunohistochemical Analysis.	Biomedicines	2026	https://conductscience.org/library/papers/41595625	PubMed
41,079,075	Decoding infantile hemangioma: cellular dynamics, molecular signals, and microenvironmental influences.	Front Oncol	2025	https://conductscience.org/library/papers/41079075	PubMed
40,722,380	Different Expression of Vascularization and Inflammatory Regulators in Cells Derived from Oral Mucosa and Limbus.	Bioengineering (Basel)	2025	https://conductscience.org/library/papers/40722380	PubMed
40,247,020	Bioinstructive scaffolds enhance stem cell engraftment for functional tissue regeneration.	Nat Mater	2025	https://conductscience.org/library/papers/40247020	PubMed
39,752,011	The molecular mechanism of gemcitabine in inhibiting the HIF-1α/VEGFB/FGF2/FGFR1 signaling pathway for ovarian cancer treatment.	Discov Oncol	2025	https://conductscience.org/library/papers/39752011	PubMed
39,625,344	aYAP1-2 contributes to bFGF-induced proliferation In gastric cancer.	Anticancer Drugs	2025	https://conductscience.org/library/papers/39625344	PubMed
38,375,209	Scaling up production of recombinant human basic fibroblast growth factor in an Escherichia coli BL21(DE3) plysS strain and evaluation of its pro-wound healing efficacy.	Front Pharmacol	2023	https://conductscience.org/library/papers/38375209	PubMed

1 to 10 of 68

See all 68 cited by

Genes0

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

None in this release.

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed: 2026-11-06; PubMed
iCite: 2026-11-05; iCite
PMC's ID file: 2026-11-05; PMC's ID file
NIH RePORTER's grant and paper links: 2026-11-01; NIH RePORTER's grant and paper links
Trials: 2026-11-12
Gene search: 2026-11-11
Pipelines: 2026-09-18

Sources 11

ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
HGNCCC0
iCiteCC BY 4.0
NCBI GenePublic domain (US government)
NIH RePORTER's grant and paper linksPublic domain
Open TargetsCC0 1.0
PMC's ID filePublic domain (US government)
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0

Each source's terms

ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
HGNCCC0: https://www.genenames.org/about/license/
iCiteCC BY 4.0
NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/10716624

GET https://conductscience.org/api/papers/v1/10716624/cited_by?page=2

API reference For AI assistants